You are here

FDA Approves First Wearable Device for Adolescent IBS Pain

Over Half of Patients Had Reduced Pain Levels of 30% or More

The FDA has approved the IB-Stim non-surgical prescription device (Innovative Health Solutions) to help reduce functional abdominal pain in adolescents with irritable bowel syndrome (IBS) through nerve stimulation.

The device is designed for patients aged between 11 and 18 years. The small, battery-powered device, which is placed behind the ear, continuously emits mild electrical pulses that target certain branches and bundles of cranial nerves. After five days, the device is replaced.

Patients can use the device for up to three consecutive weeks to help reduce the abdominal pain associated with IBS, in combination with other therapies.

The FDA granted the IB-Stim a 510(k) clearance through its de novo product review pathway. The agency had also authorized similar versions of the device, including the NSS-2 Bridge to reduce symptoms of opioid withdrawal, in 2017.

In a clinical study, 50 adolescents with IBS were randomized against a sham treatment. After three weeks, patients who received IB-Stim saw greater improvements compared to baseline scores that measured the frequency, severity, and duration of pain.

Also, 52% of patients reported at least a 30% drop in their usual pain levels over the three weeks, and 59% reported at least a 30% drop in their worst levels of pain.

By comparison, of patients who received the placebo treatment, 30% and 26% reached the same levels in their typical and worst pain scores, respectively.

Source: FierceBiotech, June 11, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation